In vivo and in vitro tumour models have been instrumental in validating AT1R as a key therapeutic target by elucidating its role in promoting a desmoplastic, fibrotic and immunosuppressive tumour microenvironment [51, 52, 53, 54]. This evidence concerns the gene AGTR1 and neoplasm.